Protective Effects of cis-2-Dodecenoic Acid in an Experimental Mouse Model of Vaginal Candidiasis.

Dong Liang Yang; Yu Qian Zhang; Yan Ling HU; Li Xing Weng; Gui Sheng Zeng; Lian Hui Wang

Return

Protective Effects of cis-2-Dodecenoic Acid in an Experimental Mouse Model of Vaginal Candidiasis.

Author: Dong Liang YANG ^{1
,

2} ; Yu Qian ZHANG ³ ; Yan Ling HU ³ ; Li Xing WENG ⁴ ; Gui Sheng ZENG ⁵ ; Lian Hui WANG ³
Author Information

1. Key Laboratory for Organic Electronics and Information Displays & Jiangsu Key Laboratory for Biosensors, Institute of Advanced Materials (IAM), Nanjing University of Posts and Telecommunications, Nanjing 210023, Jiangsu, China
2. School of Physical and Mathematical Sciences, Nanjing Tech University, Nanjing 211816, Jiangsu, China.
3. Key Laboratory for Organic Electronics and Information Displays & Jiangsu Key Laboratory for Biosensors, Institute of Advanced Materials (IAM), Nanjing University of Posts and Telecommunications, Nanjing 210023, Jiangsu, China.
4. College of Geography and Biological Information, Nanjing University of Posts and Telecommunications, Nanjing 210023, Jiangsu, China.
5. Institute of Molecular and Cell Biology, 61 Biopolis Drive, Proteos, Singapore, 138673, Singapore.
Publication Type:Journal Article
Keywords: C. albicans; Candidiasis; Virulence factor; cis-2-dodecenoic acid
MeSH: Animals; Candida albicans; drug effects; metabolism; pathogenicity; physiology; Candidiasis, Vulvovaginal; drug therapy; genetics; immunology; microbiology; Chemokine CCL2; genetics; immunology; Disease Models, Animal; Fatty Acids, Monounsaturated; administration & dosage; Female; Fungal Proteins; genetics; metabolism; Humans; Insulin-Like Growth Factor Binding Protein 3; genetics; immunology; Mice; Virulence; drug effects; Virulence Factors; genetics; metabolism
From: Biomedical and Environmental Sciences 2018;31(11):816-828
CountryChina
Language:English
Abstract: OBJECTIVE:To evaluate the efficacy of cis-2-dodecenoic acid (BDSF) in the treatment and prevention of vaginal candidiasis in vivo.
METHODS:The activities of different concentrations of BDSF against the virulence factors of Candida albicans (C. albicans) were determined in vitro. An experimental mouse model of Candida vaginitis was treated with 250 μmol/L BDSF. Treatment efficiency was evaluated in accordance with vaginal fungal burden and inflammation symptoms.
RESULTS:In vitro experiments indicated that BDSF attenuated the adhesion and damage of C. albicans to epithelial cells by decreasing phospholipase secretion and blocking filament formation. Treatment with 30 μmol/L BDSF reduced the adhesion and damage of C. albicans to epithelial cells by 36.9% and 42.3%, respectively. Treatment with 200 μmol/L BDSF completely inhibited phospholipase activity. In vivo mouse experiments demonstrated that BDSF could effectively eliminate vaginal infection and relieve inflammatory symptoms. Four days of treatment with 250 μmol/L BDSF reduced vaginal fungal loads by 6-fold and depressed inflammation. Moreover, BDSF treatment decreased the expression levels of the inflammatory chemokine-associated genes MCP-1 and IGFBP3 by 2.5- and 2-fold, respectively.
CONCLUSION:BDSF is a novel alternative drug that can efficiently control vaginal candidiasis by inhibiting the virulence factors of C. albicans.